Pharmafile Logo

Outcomes-based payment

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

Novartis legal head resigns over Cohen payments

General counsel steps down, but Novartis still facing difficult questions

- PMLiVE

Daily Brief

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Novartis launches remote clinical trial app

FocalView will allow patients to participate in ophthalmology trials

- PMLiVE

New centre aims to Catapult UK into cell and gene therapy lead

The UK is hoping to cement its lead as a world leader in cell and gene therapy manufacturing thanks to a new ‘Catapult’ centre opened today.

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

- PMLiVE

GSK buys Novartis out of consumer health JV after ditching Pfizer bid

Will pay $13bn for the 36.5% stake owned by the Swiss drug maker

- PMLiVE

Can value-based healthcare take off and reach for the skies?

Are companies willing to contribute to the change in the healthcare system?

- PMLiVE

Novartis pushes ‘virtual’ clinical trial concept

Teams up with Science 37 to run ten digital-based trials over the next three years

Novartis telemedicine service to be ramped up in Ghana

Country's health service selects it as part of the national eHealth strategy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links